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The PLoS Medicine Debate
Background to the debate: Current guidelines recommend that all fever episodes in African children be treated 
presumptively with antimalarial drugs. But declining 
malarial transmission in parts of sub-Saharan Africa, 
declining proportions of fevers due to malaria, and the 
availability of rapid diagnostic tests mean it may be time 
for this policy to change. This debate examines whether 
enough evidence exists to support abandoning presumptive 
treatment and whether African health systems have the 
capacity to support a shift toward laboratory-confirmed 
rather than presumptive diagnosis and treatment of malaria 
in children under five. 
In this Viewpoint, Mike English and colleagues argue against 
abandoning presumptive treatment for under-fives. Blaise Genton 
and colleagues present the opposing Viewpoint in a related article: 
D’Acremont V, Lengeler C, Mshinda H, Mtasiwa D, Tanner M, 
et al. (2009) Time to move from presumptive malaria treatment 
to laboratory-confirmed diagnosis and treatment in African 
children with fever. PLoS Med 6(1): e252. doi:10.1371/journal.
pmed.0050252
No one would argue against the tenet that children in low-
income settings should receive the highest quality of clinical 
care. System-wide provision of accurate and reliable treatment 
to those with true malaria is a major goal. However, we 
caution against rapid universal policy change that abandons 
presumptive antimalarial treatment for African children 
under five with fever for two reasons. Firstly, important 
evidence gaps remain. Secondly, the health system capacity 
to implement such a policy shift has not been demonstrated. 
If anxiety about drug costs (which are falling) and optimism 
that malaria is being defeated drive rapid policy change, this 
may result in hurried policy doing more harm than good. 
Minimising the risk of death or severe disease is at the heart 
of the presumptive treatment strategy. Diagnostics potentially 
allow treatment to be restricted to those truly with disease. 
However, where diagnostics, or their use, are imperfect, we 
remain with a (now untreated) population at risk. While 
rapid diagnostic tests (RDTs) perform relatively well in 
research studies, limited data on performance in routine 
settings suggest relatively poor sensitivity overall (65%) and 
worrying variability between sites (19%–86% sensitivity) [1]. 
How great a risk are we prepared to take in terms of mortality 
and morbidity from missed malaria cases? Recent economic 
evaluations support treatment contingent on RDT diagnosis, 
particularly where malaria prevalence is low [2,3]. However, 
such models still rely on a “best guess” of the risk of no 
treatment in a truly infected child. Furthermore, this best guess 
often assumes infection in a semi-immune child. This scenario 
will no longer be relevant as infection rates decline because 
even young children will be “non-immune” and potentially 
at much higher risk. Limited data suggest that the risk of 
failure to detect true malaria in febrile children is very low [4]. 
However, these studies are based on active follow-up, and do 
not measure the risks of serious morbidity and mortality from 
a failed diagnostic process in real-life settings where there are 
considerable barriers to accessing (re-)treatment. 
Malaria prevalence has declined in some countries. 
However, malaria prevention efforts across the continent 
remain inadequate [5], and considerable heterogeneity 
persists within countries, with relatively high prevalence 
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Provenance: This Debate arose from an uncommissioned submission by Blaise 
Genton and colleagues that was reviewed by Mike English. We then commissioned 
contributions to a Debate from each author, which were not otherwise peer 
reviewed.
The PLoS Medicine Debate discusses important but controversial issues in clinical 
practice, public health policy, or health in general.
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(more than 40%) recently reported in febrile under-fives 
in Tanzania and Uganda [1,6,7]. Ideally, countries would 
base their diagnostic strategy on detailed data on local 
epidemiology and disease risks [8]; however, most countries 
simply do not have the right information, and may lack the 
capacity to vary diagnostic strategies by transmission level. 
The beliefs and behaviours of health workers and patients 
are central to improving the rational use of antimalarials. 
In operational settings health workers frequently ignore 
diagnostic results and prescribe antimalarials to negative 
cases [9] for reasons that seem to them entirely justified [10]. 
This behaviour significantly impairs the cost-effectiveness 
of introducing confirmed diagnosis [3,11]. Furthermore, 
presumptive treatment by community health workers and 
retailers is increasingly being promoted with the justifiable 
aim of improving child survival by increasing access to care. 
However, a policy context that restricts antimalarials to 
confirmed diagnoses in formal care settings but promotes 
presumptive treatment in the community will send mixed 
messages to patients and health workers, and reinforce the view 
that all fever (and almost all non-specific illness) is “malaria”. A 
negative diagnostic test may do little to change this view [9,10]. 
Moreover, introducing universal diagnostic testing is not 
a matter of behaviour change alone. There are also major 
health system challenges. We have proven ourselves incapable 
of even purchasing and delivering drugs reliably [12]. Adding 
a new commodity that requires distribution and quality 
control [1] will be a considerable challenge, and arguably 
one that should be taken on only once we have achieved high 
coverage with effective drugs and prevention. 
Improving diagnosis and treatment of febrile illness is 
a key priority. However, before embarking on a universal 
policy change we need: (1) improved data on local malaria 
epidemiology, perhaps obtained initially through specific 
sentinel sites; (2) improved implementation of confirmed 
diagnosis and treatment in older children and adults, 
specifically tackling health worker and patient behaviours 
and beliefs; (3) information on the safety and acceptability 
of withholding antimalarials in young febrile children who 
test negative by RDT for malaria; and (4) development 
of effective quality control processes to support RDT 
introduction. Much of this work could be undertaken as part 
of pragmatic, large-scale effectiveness assessments in areas 
already making excellent progress in controlling malaria. 
While such work is undertaken we must not lose sight of the 
necessity to reduce current, inequitable gaps in coverage with 
established malaria prevention and treatment strategies and 
primary health care more broadly. 
English and Colleagues’ Response to Genton 
and Colleagues’ Viewpoint:
In this section, English and colleagues respond to the points raised by 
Genton and colleagues in their opposing Viewpoint: D’Acremont V, 
Lengeler C, Mshinda H, Mtasiwa D, Tanner M, et al. (2009) Time 
to move from presumptive malaria treatment to laboratory-confirmed 
diagnosis and treatment in African children with fever. PLoS Med 
6(1): e252. doi:10.1371/journal.pmed.0050252
Genton and colleagues present the case for a shift from 
presumptive antimalarial treatment for all febrile children 
in malaria-endemic areas to a policy of treatment based on 
confirmatory diagnostic testing with an RDT. The logic of 
this argument is that: (1) we have the diagnostic tools; (2) 
drugs are costly, and unnecessary treatment exposes children 
to needless risks; (3) malaria prevalence has declined 
sufficiently so universal treatment is neither clinically nor 
economically rational; and (4) over-diagnosis of malaria 
results in inadequate treatment of other illnesses. Implicit in 
their suggestion for a comprehensive policy change now is 
that health systems and health workers are ready for it. As we 
have already described in our Viewpoint, there is very little 
published data on RDT use in real-life settings and what there 
is suggests their performance is currently far from convincing. 
And while we agree that malaria prevalence is declining 
in many areas, we maintain that malaria epidemiology 
varies considerably and individual countries lack adequate 
information on local epidemiology and disease risk to 
meaningfully tailor their diagnostic strategies by transmission 
level.
Perhaps the most important barriers to improving the 
rational use of antimalarials are the limited capacities of 
health systems and health workers. Genton and colleagues 
imply that changing the mindset of health workers and 
patients will be relatively straightforward. It is more likely 
that making it acceptable to “deny” a patient (especially a 
young, febrile child) an antimalarial will be a mammoth 
task. After all, we have made no progress in reducing the use 
of antimalarials to date even in adults in low-transmission 
settings—perhaps a useful place to begin rigorously 
implementing a policy of treatment based on a positive 
diagnosis, as this group represents a large fraction of drug 
costs.
Furthermore, Genton and colleagues argue (but provide 
no evidence) that identifying cases negative for malaria 
will improve overall quality of care. There is in fact little 
reassurance that availability of malaria tests makes health 
workers better diagnosticians, as they often ignore all 
guidelines and follow norms that are not obviously rational 
[10] but may reflect “bedside rationing” in severely resource-
constrained environments. Indeed, the current Integrated 
Management of Childhood Illness approach already 
encourages assessment and treatment of all likely diagnoses 
in under-fives irrespective of the presence of malaria. We 
cannot blame the provision of poor quality primary care 
on the lack of malaria diagnostics, and it seems unlikely 
that their provision will automatically improve availability 
of appropriate resources for treating other conditions and 
improving care more generally. Such general improvement 
needs to be addressed as a priority in its own right. 
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